Abstract: This invention relates to the application of the highly conserved sequences of viral genome, especially from a highly conserved domain of enteroviral genome as templates to design target small ligand RNAs (sliRNAs). The resulting sliRNAs are therapeutically active ingredients in the treatment of the related diseases caused by pathological angiogenesis.

Abstract: This invention relates to the application of the highly conserved sequences of viral genome, especially from a highly conserved domain of enteroviral genome as templates to design target small ligand RNAs (sliRNAs). The resulting sliRNAs are therapeutically active ingredients in the treatment of the related diseases caused by pathological angiogenesis.

Abstract: This invention relates to the application of the highly conserved sequences of viral genome, especially from a highly conserved domain of enteroviral genome as templates to design target small ligand RNAs (sliRNAs). The resulting sliRNAs are therapeutically active ingredients in the treatment of the related diseases caused by pathological angiogenesis.

Abstract: This invention relates to the application of the highly conserved sequences of viral genome, especially from a highly conserved domain of enteroviral genome as templates to design target small ligand RNAs (sliRNAs). The resulting sliRNAs are therapeutically active ingredients in the treatment of the related diseases caused by pathological angiogenesis.

Abstract: Liposome formulations for administration of a boronic acid compound are described. The liposomes are comprised of a phospholipid having two acyl chains with between 20-22 carbon atoms in each chain and a boronic acid compound entrapped in the liposomes. In a preferred embodiment, the boronic acid compound is in the form of a complex with meglumine.

Abstract: The invention comprises stabilized polynucleotide complexes that have a cryoprotectant and are lyophilized. Cryoprotectant compounds comprise carbohydrates or sugars, preferably lactose and sucrose, but also glucose, maltodextrins, mannitol, sorbitol, trehalose, and others. Other suitable cryoprotectants include amino acids such as betaines and prolines. Polynucleotide complexes stabilized according to the invention can be used for transfection, and exhibit improved tranfection efficiency with respect to polynucleotide complexes without cryoprotection.

Abstract: The present invention relates to a method of making a liposome composition. In particular, the invention relates to a method of making liposomes targeted to a specific cell receptor for delivery of a liposome-entrapped drug to the cell. In one embodiment, the process involves the incorporation of lipid-linkers to the surface of pre-formed liposomes, preferably at a higher temperature, followed by the conjugation of one or more temperature-sensitive ligands to the linkers associated with the liposome surface at a lower temperature to avoid deactivation of the temperature sensitive ligands. The present invention also is directed to a product prepared according to the foregoing process, and its use to treat subjects. The present invention is also directed to a kit containing lipid-linker, ligand and pre-formed liposome.

Abstract: Cationic lipids are provided which are useful in the preparation of liposomes and other lipid vesicle carriers. The lipids of the invention are particularly useful as carriers of nucleic acids and other negatively charged substances, for delivery to cells.

Abstract: This present invention provides a class of gene transfection reagents, which have a structure containing a nucleic acid binding domain and sugar targeting domain. The compounds are easy to synthesize and formulate. The formulated compound associates with DNA to form small particles with nearly neutral surface charge. The sugar domain plays a role as a tissue target ligand located on the surface of the nucleic acid complex, which promotes the receptor-mediated gene transfection. In the presence of proteins, these DNA complexes do not bind with proteins to form precipitates. The complexes are also stable when stored at 4° C. for a long time.

Abstract: Methods for introducing nucleic acids into mammalian cells are provided which use imidazolium lipids. The imidazolium lipids have the formula: wherein R1 and R2 each independently represent a C8-C24 saturated or unsaturated hydrocarbon chain, uninterrupted or interrupted by from 1 to 3 heteroatom moieties selected from —O—, —S—, —NH— and —NR—; X represents —CH2—, —O—, —S—, —NH— or —NR—; wherein R is a lower alkyl group having from 1 to 4 carbon atoms; n is an integer of from 1 to 2; and A− is an anion.

Abstract: Methods and compositions are provided for the introduction of polyanionic molecules, in particular, nucleic acids, into mammalian cells using certain phosphatidyl ethanolamines as helper lipids in conjunction with various cationic lipids. In particular, cationic lipid-mediated transfection of mammalian cells is improved by the use of lipid carriers comprising DLPE or DiPPE and cationic lipids.

Abstract: Compounds of the formula: ##STR1## are provided, in which R.sup.1 and R.sup.2 each independently represent a C.sub.8 -C.sub.24 saturated or unsaturated hydrocarbon chain, which is optionally interrupted by from 1 to 3 heteroatom moieties, such as --O--, --S--, --NH-- and --NR--. The symbol X represents --CH.sub.2 --, --O--, --S--, --NH-- or --NR--. The R group for each of the --NR-- moieties represents an alkyl group having from 1 to 4 carbon atoms. Finally, the subscript n represents the integer 1 or 2, and A.sup.- represents an anion, preferably chloride or citrate.

Abstract: The invention separates defined, active complexes by a characteristic from Defined, active complexes that share a particular physicochemical characteristic such as density, surface charge or particle size are separated from complexes formed by the association of a polynucleotide with a transfecting component that increases transfection activity, such as a lipid, cationic lipid, liposome, peptide, cationic peptide, dendrimer or polycation. In a preferred embodiment, polynucleotide-transfecting component complexes are ultracentrifuged to resolve one or more bands corresponding to complexes having a specific polynucleotide-transfecting component interaction. Polynucleotide complexes having a cationic liposome transfecting component resolve into two primary bands corresponding to complexes formed either under excess lipid conditions or under excess polynucleotide conditions.

Abstract: Cationic derivatives of biguanide are provided, which are useful in the preparation of lipid carriers for mediating transfection of mammalian cells in vivo and in vitro.

Abstract: Polynucleotide complexes are stabilized by adding a cryoprotectant compound and lyophilizing the resulting formulation. The lyophilized formulations are milled or sieved into a dry powder formulation which may be used to deliver the polynucleotide complex. Delivery of the polynucleotide to a desired cell tissue is accomplished by contacting the tissue with the powder to rehydrate it. In a preferred embodiment, a dry powder formulation is used to transfer genetic information to the cells of the respiratory tract.